¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"human zona binding assay"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • radioreceptor assay
    ¹æ»ç¼±¼ö¿ëÃ¼ÃøÁ¤(¹ý)
  • radial partition immunofluorometric assay
    ¹æ»çºÐÇҸ鿪Çü±¤ÃøÁ¤
  • sperm penetration assay
    Á¤ÀÚ°üÅëÃøÁ¤, Á¤ÀÚ°üÅë°Ë»ç
  • superoxide assay
    Ãʰú»êÈ­¹°ÃøÁ¤
  • antihemophilic human plasma
    Ç×Ç÷¿ìº´Ç÷Àå
  • anti-human globulin
    Ç×»ç¶÷±Û·ÎºÒ¸°, Ç×ÀÎü±Û·ÎºÒ¸°
  • enteric cytopathogenic human orphan virus
    ¿¡ÄÚ¹ÙÀÌ·¯½º
  • human
    »ç¶÷, Àΰ£
  • human antihemophilic factor
    »ç¶÷Ç×Ç÷¿ìº´ÀÎÀÚ
  • human blood index
    »ç¶÷Ç÷¾×Áö¼ö
  • human chorionic somatomammotropin
    »ç¶÷À¶¸ð¸öÁ¥»ùÀÚ±ØÈ£¸£¸ó, »ç¶÷À¶¸ð¼Ò¸¶Å丶¸ðÆ®·ÎÇÉ
  • human diploid cell vaccine
    »ç¶÷µÎ¹è¼ö¼¼Æ÷¹é½Å
  • human ecology
    Àηù»ýÅÂÇÐ
  • human experiment
    ÀÎü½ÇÇè
  • human genetics
    »ç¶÷À¯ÀüÇÐ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • double-sandwich enzyme-linked immunosorbent assay
    °ãÈ¿¼Ò¸é¿ªÃøÁ¤¹ý
  • enzyme assay
    È¿¼ÒÃøÁ¤
  • enzyme-linked immunosorbent assay
    È¿¼Ò¸é¿ªÃøÁ¤¹ý
  • foam stability assay
    °Åǰ¾ÈÁ¤ÃøÁ¤
  • focus assay
    ¹ÙÀÌ·¯½ºÆ÷Ä¿½ºÃøÁ¤
  • hemagglutination assay
    Ç÷±¸ÀÀÁýÃøÁ¤(¹ý)
  • hemolytic plaque assay
    ¿ëÇ÷ÆÇÃøÁ¤¹ý, ¿ëÇ÷ÇöóÅ©ÃøÁ¤¹ý
  • immunofluorescence assay
    ¸é¿ªÇü±¤ÃøÁ¤
  • immunoradiometric assay
    ¸é¿ª¹æ»çÃøÁ¤(¹ý)
  • interference assay
    °£¼·ÃøÁ¤
  • lymphocytotoxicity assay
    ¸²ÇÁ±¸¼¼Æ÷µ¶¼ºÃøÁ¤
  • microcytotoxicity assay
    ¹Ì¼¼¼¼Æ÷µ¶¼ºÃøÁ¤
  • plaque assay
    ÆÇÃøÁ¤¹ý, ÇöóÅ©ÃøÁ¤¹ý
  • radial partition immunofluorometric assay
    ¹æ»ç¼ººÐÇҸ鿪Çü±¤ÃøÁ¤
  • radiochemical assay
    ¹æ»çÈ­ÇÐÃøÁ¤(¹ý)
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • immunofluorescence assay
    ¸é¿ªÇü±¤°Ë»ç
  • immunometric assay
    ¸é¿ª°è·®<--°èÃø>°Ë»ç
  • immunoradiometric assay
    ¸é¿ª¹æ»çÃøÁ¤(¹ý)
  • plaque assay
    ÇöóÅ© ÃøÁ¤¹ý
  • plaque assay, hemolytic
    ¿ëÇ÷¼º ÇöóÅ© Çü¼º½ÃÇè
  • predictive assay
    È¿°ú¿¹Ãø½ÃÇè
  • radial partition immunofluorometric assay
    ¹æ»ê¼ººÐÇҸ鿪Çü±¤°èÃø¹ý
  • radiochemical assay
    ¹æ»çÈ­ÇÐÃøÁ¤¹ý
  • radioreceptor assay
    ¹æ»ç¼±¼ö¿ëÃ¼ÃøÁ¤
  • radioreceptor assay
    ¹æ»ç¼ö¿ëÃ¼ÃøÁ¤¹ý
  • receptor assay
    ¼ö¿ëÃ¼ÃøÁ¤
  • ECHO virus =enteric cytopathogenic human orphan v.
    ¿¡ÄÚ¹ÙÀÌ·¯½º(¼Ó).
  • Enteric cytopathogenic human orphan virus =ECHO v.
    ¿¡ÄÚ¹ÙÀÌ·¯½º(¼Ó).
  • Enteric cytopathogenic human orphan virus =ECHO virus
    ¿¡ÄÚ¹ÙÀÌ·¯½º
  • HCG=>human chorionic gonadotropin
    »ç¶÷À¶¸ð¼º ¼º¼±ÀÚ±ØÈ£¸£¸ó
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • binding
    ¹­À½, °áÇÕ.
  • binding activity
    °áÇÕȰ¼º(Ì¿ùêüÀàõ).
  • binding activity
    ¸é¿ª°áÇÕȰ¼º(Ì¿ùêüÀàõ).
  • binding affinity
    °áÇÕģȭ¼º(Ì¿ùêöÑûúàõ)
  • binding displacement analysis
    °áÇÕº¯À§ºÐ¼®(Ì¿ùêܨêÈÝÂà°).
  • binding energy
    °áÇÕ¿¡³ÊÁö
  • binding energy
    °áÇÕ(Ì¿ùê)¿¡³ÊÁö
  • binding orbit
    °áÇձ˵µ(Ì¿ùêÏùÔ³).
  • binding site
    °áÇÕºÎÀ§.
  • binding site
    °á ÇÕºÎÀ§.
  • calcium-binding protein
    Ä®½· °áÇմܹé(Ì¿ùêÓ±ÛÜ)
  • cap binding protein
    ĸ°áÇմܹéÁú
  • cell growth,ligand receptor binding
    ¸®°£µå¼ö¿ë±â°áÇÕ (¡­áôé»ÐïÌ¿ùê)
  • cellular retinol-binding protein
    ¼¼Æ÷³» ·¹Æ¼³î °áÇմܹé
  • competitive protein binding radioassay
    °æÇÕÀû ´Ü¹é°áÇÕ¹æ»çºÐ¼®(¹ý)(¡­Ó±ÛÜ Ì¿ùêÛ¯ÞÒÝÂà°Ûö).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • cortisol-binding globulin
    "ÄÚÆ¼¼Ö°áÇÕ(Ì¿ùê) ±Û·ÎºÒ¸°, (ÔÒ) transcortin"
  • cortisol-binding protein
    ÄÚÆ¼¼Ö°áÇÕ(Ì¿ùê) ´Ü¹éÁú(Ó±ÛÜòõ) (ÔÒ) transcortin
  • DNA binding protein
    DNA °áÇÕ ´Ü¹éÁú(Ì¿ùêÓ±ÛÜòõ) (ÔÒ) single strand binding protein
  • excluded site binding
    ¹èÁ¦(ÛÉð¶)ÀÚ¸® °áÇÕ(Ì¿ùê)
  • fraction-antibody binding
    ºÎºÐÇ×ü °áÇÕ(Ý»ÝÂù÷ô÷Ì¿ùê)
  • GTP-binding protein
    GTP°áÇÕ ´Ü¹éÁú(Ì¿ùêÓ±ÛÜòõ)
  • guanine-nucleotide-binding protein
    ±¸¾Æ´Ñ´©Å¬·¹¿ÀŸÀÌµå °áÇÕ ´Ü¹éÁú(Ì¿ùêÓ±ÛÜòõ)
  • independent binding
    µ¶¸³°áÇÕ(Լء̿ùê)
  • iron-binding globulin
    ö°áÇÕ(ôÑÌ¿ùê) ±Û·Îºí¸°
  • latent iron-binding capacity
    ÀáÀçö°áÇÕ´É(íÖî¤ôÑÌ¿ùêÒö)
  • macroscopic binding constant
    °Å½Ã °áÇÕ»ó¼ö(ËÝãÊÌ¿ùêßÈâ¦)
  • microscopic binding constant
    ¹Ì½Ã°áÇÕ»ó¼ö(Ú°ãÊÌ¿ùêßÈâ¦)
  • mononucleotide binding domain
    ¸ð³ë´©Å¬·¹¿ÀŸÀÌµå °áÇÕ¿µ¿ª(Ì¿ùêÖÅæ´)
  • multiple binding
    ´ÙÁß°áÇÕ(ÒýñëÌ¿ùê)
  • nonexclusive binding
    ºñ¹èŸ°áÇÕ(ÞªÛÉöâÌ¿ùê)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
CBG capillary blood gases; coronary bypass graft; corticosteroid-binding globulin; cortisol-binding glob...
FABP fatty acid-binding protein; folate-binding protein
IBC Institutional Biosafety Committee; iodine-binding capacity; iron-binding capacity; isobutyl cyanoacr...
IBP insulin-like growth factor binding protein; International Biological Program; intra-aortic balloon p...
MBP major basic protein; maltose-binding protein; management by policy; mannose-binding protein; mean bl...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
SPRIA Solid Phase Radioimmune Assay
ELISA Enzyme Linked Immuno Sorbant Assay
C-ELISA Competitive enzyme-linked immunosorbent assay
DEIA DNA enzyme immuno assay
DIG-ELISA Diffusion-In-Gel Enzyme Linked Immunosorbent Assay
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • zona perforata
    õ°ø´ë
    ¿Í¿ì°ü ±âÀúÆÇÀÇ ³»Ãø ºÎºÐ.
  • zona pigmentosa
    »ö¼Ò´ë
  • zona proliferativa
    Áõ½Ä´ë
    Áõ½ÄÃþ.
  • zona reaction
    Åõ¸í´ë ¹ÝÀÀ
  • zona reservata
    ¿¹ºñ ¿¬°ñ´ë
    ¿¹ºñÃþ.
  • zona spongiosa
    ÇØ¸éÃþ, ÇØ¸é´ë
  • zona superficialis
    õ´ë
    Ç¥Ãþ
  • zona tendinosa
    °Ç»ó´ë
  • zona vasculosa
    ¸Æ°ü´ë
    Ç÷°ü Åë·ÎÀÇ ±¸¸ÛÀ» dzºÎÇÏ°Ô °¡Áø À¯µ¹»ó ¿Í¿¡ ÀÖ´Â ºÎºÐ.
  • citrated normal human plasma
    Á¤»óÀÎ ±¸¿¬»ê¿° ÷°¡ Ç÷Àå
  • class I human leukocyte antigen
    Á¦ 1±Þ ÀÎü ¹éÇ÷±¸ Ç׿ø
  • class II human leukocyte antigen
    Á¦ 2±Þ ÀÎü ¹éÇ÷±¸ Ç׿ø
  • enteric cytopathogenic human orphan virus
    ¿¡ÄÚ ¹ÙÀÌ·¯½º
  • human bite
    »ç¶÷ ±³»ó
  • human chorionic gonadotropin
    »ç¶÷ À¶¸ð¼º ¼º¼± ÀÚ±Ø È£¸£¸ó
    ÀÌ´Â glyco
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
plaque assay 1. <investigation> Assay for virus in which a dilute solution of the virus is applied to a culture dish containing a layer of the host cells, convective spread is prevented by making the medium very viscous. After incubation the plaques, areas in which cells have been killed (or transformed), can be recognised and the number of infective virus particles in the original suspension estimated.
2. Assay for cells producing antibody against erythrocytes or against antigen that has been bound to the erythrocytes. The cell is surrounded by a clear plaque of haemolysis. Basic principle behind the assay is the same as for the virus plaque assay.
(18 Nov 1997)
haemolytic plaque assay <investigation> A haemolytic plaque assay is a lab technique used to show that certain antibodies are secreted by antibody-making cells when these cells are mixed with red blood cells.
The mixture is spread onto a plate of agar, if a plaque appears, it means that the red blood cells have been destroyed (by haemolysis) by the antibodies.
(09 Oct 1997)
Hageman factor assay A test used to measure the activity of a blood clotting factor XII. This test may be used to evaluate excessive bleeding. Low factor XII may be seen in cases of congenital deficiency of factor XII, heparin administration and liver disease.
(27 Sep 1997)
progesterone receptor assay The progesterone receptor test (PgR assay) checks the tumour for its hormone status.
(16 Dec 1997)
hemizona assay <investigation> The hemizona assay is a laboratory test of the ability of sperm to penetrate into a human egg, first the egg is split in half, then one half is tested against the husband's sperm and the other half against sperm from a fertile man.
(09 Oct 1997)
scintillation proximity assay Assay system in which antibody or receptor molecule is bound to a bead that will emit light when _ emission from an isotope occurs in close proximity, i.e. From a radioactively labelled ligand. Avoids the need for scintillant in order to measure the amount of bound isotope and thus the amount of antigen or ligand present.
(18 Nov 1997)
hormone receptor assay A diagnostic test to determine whether a breast cancer's growth is influenced by hormones or if it can be treated with hormones.
(09 Oct 1997)
subrenal capsule assay In vivo method of screening investigative anticancer drugs and biologic response modifiers for individual cancer patients. Fresh tumour tissue is implanted under the kidney capsule of immunocompetent mice or rats; gross and histological assessments follow several days after tumour treatment in situ.
(12 Dec 1998)
nuclear run off assay <investigation, procedure> Technique for determining which genes are being actively transcribed at a given moment in an experiment by extracting nuclear material and allowing transcription to continue, then analysing the resulting RNAs.
(18 Nov 1997)
DNA filter assay <molecular biology> A lab technique used to identify the complementary base sequences of DNA. It involves immobilising the DNA on a filter and putting it in a solution that contains radioactively-labelled probe DNA or RNA molecules.
(09 Oct 1997)
double antibody sandwich assay For antigen; an application of the ELISA method in which material being tested for antigen is added to wells coated with known antibody; the presence of antigen fixed to the antibody coat can be determined either directly, by adding human antibody linked to the enzyme of the indicator system, or indirectly, by first adding unlabelled known antibody, the attachment of which to the antigen can be demonstrated by addition of immunoglobulin-specific antibody linked to the enzyme.
(05 Mar 2000)
immunochemical assay <investigation> A process that measures and identifies a specific biological substance such as an antigen.
(09 Oct 1997)
immunocytochemical assay Involves the computerised assessment of microscopic fields following direct fluorescent antibody, indirect fluorescent antibody or indirect or direct immunoperoxidase analysis of biopsy tissue from the patient. In addition to improved specificity with the removal of operator subjectivity, the quantifiability of results through computer data analysis of colour, intensity and concentration has only begun to be realised.
(05 Mar 2000)
immunoradiometric assay <immunology> A test that measures the concentration of antigens in a specimen throughserological analysis that involves mixing radioactive antibodies with the antigen in question.
(09 Oct 1997)
indirect assay For antibody; an application of the ELISA method in which serum being tested for antibody is added to wells coated with known antigen; presence of antibody bound to the antigen coat can be determined by addition of immunoglobulin-specific antibody to which is linked the enzyme of the indicator system, followed by addition of substrate to the washed aggregate.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á